Table 3 |
||||||
| Contents and results of radiotherapy (with or without chemotherapy) for postoperative recurrent esophageal cancer in past studies | ||||||
| author | year | No. | regimen | median observation period | 2-year survival rate | 5-year survival rate |
| JL Raoul12) | 1995 | 24 | RT† + CDDP*+5-FU | 14 months | 17.1% | n.a. ‡ |
| K Nemoto13) | 2001 | 33 | RT alone (21) or RT + CDDP+ 5-FU (12) | n.a. | 15% | n.a. |
| Y Nishimura11) | 2003 | 13 | RT + CDDP+5-FU | 9.5 months | 19% | n.a. |
| Y Shioyama14) | 2007 | 82 | RT ± chemotherapy | n.a. | 22% | 11% |
| K Maruyama15) | 2011 | 23 | RT ± chemotherapy | n.a. | 31% | 24% |
| Current study | 2012 | 30 | RT + CDGP§+ 5-FU | 72 months | 46.0% | 27.0% |
†RT: radiotherapy, * CDDP: cisplatin, § CDGP: nedaplatin, # 5-FU: 5-fluorouracil, ‡n.a.: not available.
Jingu et al. BMC Cancer 2012 12:542 doi:10.1186/1471-2407-12-542
